Join Phase 2 development trial designer and Cytel Consulting Statistician, James (Jim) Bolognese for a closer look at innovative methods in the crucial dose determination stage. Jim will start with a brief overview of Adaptive Design, then reveal how a single adaptive Phase 2 dose-finding design can replace the traditional sequence of two separate non-adaptive trials.
Innovations in statistics, programming and data management are changing the very nature of clinical development. Cytel thought-leaders reveal cutting-edge techniques that streamline and truly accelerate product developmental at the clinical trial, program and portfolio level.
Featuring, Simulation and biomarkers speeding development at Merck, Adaptive trial design methodology and software demonstrations, Leading independent authorities and Cytel speakers at User Group Meetings.
www.cytel.com
+1 .617.661.2011
